nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—CYP2C9—Rosuvastatin—atherosclerosis	0.0822	0.267	CbGbCtD
Epoprostenol—CYP2C9—Simvastatin—atherosclerosis	0.0764	0.248	CbGbCtD
Epoprostenol—CYP2C9—Lovastatin—atherosclerosis	0.0748	0.243	CbGbCtD
Epoprostenol—CYP2C9—Pravastatin—atherosclerosis	0.0748	0.243	CbGbCtD
Epoprostenol—PTGIS—artery—atherosclerosis	0.0182	0.134	CbGeAlD
Epoprostenol—P2RY12—artery—atherosclerosis	0.0164	0.121	CbGeAlD
Epoprostenol—PTGIS—endothelium—atherosclerosis	0.0154	0.113	CbGeAlD
Epoprostenol—PTGIS—blood vessel—atherosclerosis	0.0142	0.104	CbGeAlD
Epoprostenol—PTGIR—artery—atherosclerosis	0.0105	0.077	CbGeAlD
Epoprostenol—PTGIR—endothelium—atherosclerosis	0.00883	0.0651	CbGeAlD
Epoprostenol—PTGIR—blood vessel—atherosclerosis	0.00814	0.06	CbGeAlD
Epoprostenol—PTGIS—connective tissue—atherosclerosis	0.00727	0.0536	CbGeAlD
Epoprostenol—PTGIS—cardiovascular system—atherosclerosis	0.00632	0.0466	CbGeAlD
Epoprostenol—P2RY12—cardiovascular system—atherosclerosis	0.00569	0.042	CbGeAlD
Epoprostenol—PTGIS—adipose tissue—atherosclerosis	0.00558	0.0411	CbGeAlD
Epoprostenol—PTGIR—connective tissue—atherosclerosis	0.00417	0.0308	CbGeAlD
Epoprostenol—PTGIS—liver—atherosclerosis	0.00391	0.0288	CbGeAlD
Epoprostenol—PTGIR—cardiovascular system—atherosclerosis	0.00363	0.0268	CbGeAlD
Epoprostenol—PTGIR—adipose tissue—atherosclerosis	0.0032	0.0236	CbGeAlD
Epoprostenol—PTGIR—liver—atherosclerosis	0.00225	0.0166	CbGeAlD
Epoprostenol—CYP2C9—cardiovascular system—atherosclerosis	0.0013	0.00957	CbGeAlD
Epoprostenol—Sweating—Niacin—atherosclerosis	0.00105	0.0041	CcSEcCtD
Epoprostenol—Urinary tract infection—Pravastatin—atherosclerosis	0.00105	0.00409	CcSEcCtD
Epoprostenol—Flushing—Ezetimibe—atherosclerosis	0.00104	0.00407	CcSEcCtD
Epoprostenol—Chills—Lovastatin—atherosclerosis	0.00103	0.00401	CcSEcCtD
Epoprostenol—Cough—Rosuvastatin—atherosclerosis	0.00103	0.00401	CcSEcCtD
Epoprostenol—Angiopathy—Ezetimibe—atherosclerosis	0.00102	0.00398	CcSEcCtD
Epoprostenol—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00101	0.00395	CcSEcCtD
Epoprostenol—Sinusitis—Pravastatin—atherosclerosis	0.00101	0.00395	CcSEcCtD
Epoprostenol—Arthralgia—Rosuvastatin—atherosclerosis	0.001	0.00391	CcSEcCtD
Epoprostenol—Myalgia—Rosuvastatin—atherosclerosis	0.001	0.00391	CcSEcCtD
Epoprostenol—Flushing—Simvastatin—atherosclerosis	0.000993	0.00388	CcSEcCtD
Epoprostenol—Haemoglobin—Niacin—atherosclerosis	0.000987	0.00386	CcSEcCtD
Epoprostenol—Rhinitis—Niacin—atherosclerosis	0.000985	0.00385	CcSEcCtD
Epoprostenol—Mental disorder—Ezetimibe—atherosclerosis	0.000983	0.00384	CcSEcCtD
Epoprostenol—Haemorrhage—Niacin—atherosclerosis	0.000982	0.00384	CcSEcCtD
Epoprostenol—Flatulence—Lovastatin—atherosclerosis	0.000981	0.00383	CcSEcCtD
Epoprostenol—Hypoaesthesia—Niacin—atherosclerosis	0.000977	0.00382	CcSEcCtD
Epoprostenol—Rhinitis—Pravastatin—atherosclerosis	0.00097	0.00379	CcSEcCtD
Epoprostenol—Oedema peripheral—Niacin—atherosclerosis	0.000968	0.00378	CcSEcCtD
Epoprostenol—Confusional state—Rosuvastatin—atherosclerosis	0.000967	0.00378	CcSEcCtD
Epoprostenol—Back pain—Lovastatin—atherosclerosis	0.000963	0.00376	CcSEcCtD
Epoprostenol—Hypoaesthesia—Pravastatin—atherosclerosis	0.000962	0.00376	CcSEcCtD
Epoprostenol—Flatulence—Ezetimibe—atherosclerosis	0.000962	0.00376	CcSEcCtD
Epoprostenol—Pharyngitis—Pravastatin—atherosclerosis	0.00096	0.00375	CcSEcCtD
Epoprostenol—Chills—Simvastatin—atherosclerosis	0.00096	0.00375	CcSEcCtD
Epoprostenol—Muscle spasms—Lovastatin—atherosclerosis	0.000957	0.00374	CcSEcCtD
Epoprostenol—Infection—Rosuvastatin—atherosclerosis	0.000952	0.00372	CcSEcCtD
Epoprostenol—Back pain—Ezetimibe—atherosclerosis	0.000945	0.00369	CcSEcCtD
Epoprostenol—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00094	0.00367	CcSEcCtD
Epoprostenol—Muscle spasms—Ezetimibe—atherosclerosis	0.000939	0.00367	CcSEcCtD
Epoprostenol—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000939	0.00367	CcSEcCtD
Epoprostenol—Mental disorder—Simvastatin—atherosclerosis	0.000937	0.00366	CcSEcCtD
Epoprostenol—Tremor—Lovastatin—atherosclerosis	0.000933	0.00364	CcSEcCtD
Epoprostenol—Flatulence—Simvastatin—atherosclerosis	0.000918	0.00359	CcSEcCtD
Epoprostenol—Flushing—Niacin—atherosclerosis	0.000912	0.00356	CcSEcCtD
Epoprostenol—Anaemia—Ezetimibe—atherosclerosis	0.000903	0.00353	CcSEcCtD
Epoprostenol—Flushing—Pravastatin—atherosclerosis	0.000898	0.00351	CcSEcCtD
Epoprostenol—Cardiac disorder—Pravastatin—atherosclerosis	0.000898	0.00351	CcSEcCtD
Epoprostenol—Muscle spasms—Simvastatin—atherosclerosis	0.000895	0.0035	CcSEcCtD
Epoprostenol—Angiopathy—Niacin—atherosclerosis	0.000891	0.00348	CcSEcCtD
Epoprostenol—Chills—Niacin—atherosclerosis	0.000881	0.00344	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000873	0.00341	CcSEcCtD
Epoprostenol—Tremor—Simvastatin—atherosclerosis	0.000872	0.00341	CcSEcCtD
Epoprostenol—Chills—Pravastatin—atherosclerosis	0.000868	0.00339	CcSEcCtD
Epoprostenol—Insomnia—Rosuvastatin—atherosclerosis	0.000867	0.00339	CcSEcCtD
Epoprostenol—Palpitations—Ezetimibe—atherosclerosis	0.000863	0.00337	CcSEcCtD
Epoprostenol—Paraesthesia—Rosuvastatin—atherosclerosis	0.000861	0.00336	CcSEcCtD
Epoprostenol—Anaemia—Simvastatin—atherosclerosis	0.000861	0.00336	CcSEcCtD
Epoprostenol—Cough—Ezetimibe—atherosclerosis	0.000852	0.00333	CcSEcCtD
Epoprostenol—Arthralgia—Lovastatin—atherosclerosis	0.000848	0.00331	CcSEcCtD
Epoprostenol—Chest pain—Lovastatin—atherosclerosis	0.000848	0.00331	CcSEcCtD
Epoprostenol—Myalgia—Lovastatin—atherosclerosis	0.000848	0.00331	CcSEcCtD
Epoprostenol—Anxiety—Lovastatin—atherosclerosis	0.000845	0.0033	CcSEcCtD
Epoprostenol—Dyspepsia—Rosuvastatin—atherosclerosis	0.000844	0.0033	CcSEcCtD
Epoprostenol—Flatulence—Niacin—atherosclerosis	0.000843	0.00329	CcSEcCtD
Epoprostenol—Tension—Niacin—atherosclerosis	0.000839	0.00328	CcSEcCtD
Epoprostenol—Arthralgia—Ezetimibe—atherosclerosis	0.000831	0.00325	CcSEcCtD
Epoprostenol—Chest pain—Ezetimibe—atherosclerosis	0.000831	0.00325	CcSEcCtD
Epoprostenol—Myalgia—Ezetimibe—atherosclerosis	0.000831	0.00325	CcSEcCtD
Epoprostenol—Nervousness—Niacin—atherosclerosis	0.00083	0.00324	CcSEcCtD
Epoprostenol—Flatulence—Pravastatin—atherosclerosis	0.00083	0.00324	CcSEcCtD
Epoprostenol—Dry mouth—Lovastatin—atherosclerosis	0.000829	0.00324	CcSEcCtD
Epoprostenol—Tension—Pravastatin—atherosclerosis	0.000826	0.00323	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000826	0.00323	CcSEcCtD
Epoprostenol—Muscle spasms—Niacin—atherosclerosis	0.000822	0.00321	CcSEcCtD
Epoprostenol—Pain—Rosuvastatin—atherosclerosis	0.00082	0.0032	CcSEcCtD
Epoprostenol—Constipation—Rosuvastatin—atherosclerosis	0.00082	0.0032	CcSEcCtD
Epoprostenol—Confusional state—Lovastatin—atherosclerosis	0.000819	0.0032	CcSEcCtD
Epoprostenol—Nervousness—Pravastatin—atherosclerosis	0.000818	0.00319	CcSEcCtD
Epoprostenol—Dry mouth—Ezetimibe—atherosclerosis	0.000813	0.00318	CcSEcCtD
Epoprostenol—Anaphylactic shock—Lovastatin—atherosclerosis	0.000812	0.00317	CcSEcCtD
Epoprostenol—Muscle spasms—Pravastatin—atherosclerosis	0.000809	0.00316	CcSEcCtD
Epoprostenol—Infection—Lovastatin—atherosclerosis	0.000807	0.00315	CcSEcCtD
Epoprostenol—Confusional state—Ezetimibe—atherosclerosis	0.000804	0.00314	CcSEcCtD
Epoprostenol—CYP2C9—liver—atherosclerosis	0.000803	0.00592	CbGeAlD
Epoprostenol—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000797	0.00311	CcSEcCtD
Epoprostenol—Thrombocytopenia—Lovastatin—atherosclerosis	0.000796	0.00311	CcSEcCtD
Epoprostenol—Arthralgia—Simvastatin—atherosclerosis	0.000793	0.0031	CcSEcCtD
Epoprostenol—Myalgia—Simvastatin—atherosclerosis	0.000793	0.0031	CcSEcCtD
Epoprostenol—Chest pain—Simvastatin—atherosclerosis	0.000793	0.0031	CcSEcCtD
Epoprostenol—Infection—Ezetimibe—atherosclerosis	0.000792	0.00309	CcSEcCtD
Epoprostenol—Anxiety—Simvastatin—atherosclerosis	0.00079	0.00309	CcSEcCtD
Epoprostenol—Tremor—Pravastatin—atherosclerosis	0.000789	0.00308	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000784	0.00306	CcSEcCtD
Epoprostenol—Nervous system disorder—Ezetimibe—atherosclerosis	0.000782	0.00305	CcSEcCtD
Epoprostenol—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00078	0.00305	CcSEcCtD
Epoprostenol—Anaemia—Pravastatin—atherosclerosis	0.000778	0.00304	CcSEcCtD
Epoprostenol—Anorexia—Lovastatin—atherosclerosis	0.000774	0.00303	CcSEcCtD
Epoprostenol—Skin disorder—Ezetimibe—atherosclerosis	0.000774	0.00302	CcSEcCtD
Epoprostenol—Syncope—Niacin—atherosclerosis	0.000767	0.003	CcSEcCtD
Epoprostenol—Confusional state—Simvastatin—atherosclerosis	0.000766	0.00299	CcSEcCtD
Epoprostenol—Urticaria—Rosuvastatin—atherosclerosis	0.000762	0.00298	CcSEcCtD
Epoprostenol—Oedema—Simvastatin—atherosclerosis	0.00076	0.00297	CcSEcCtD
Epoprostenol—Anaphylactic shock—Simvastatin—atherosclerosis	0.00076	0.00297	CcSEcCtD
Epoprostenol—Abdominal pain—Rosuvastatin—atherosclerosis	0.000758	0.00296	CcSEcCtD
Epoprostenol—Palpitations—Niacin—atherosclerosis	0.000756	0.00295	CcSEcCtD
Epoprostenol—Infection—Simvastatin—atherosclerosis	0.000755	0.00295	CcSEcCtD
Epoprostenol—Loss of consciousness—Niacin—atherosclerosis	0.000752	0.00294	CcSEcCtD
Epoprostenol—Cough—Niacin—atherosclerosis	0.000746	0.00292	CcSEcCtD
Epoprostenol—Thrombocytopenia—Simvastatin—atherosclerosis	0.000744	0.00291	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00074	0.00289	CcSEcCtD
Epoprostenol—Insomnia—Lovastatin—atherosclerosis	0.000735	0.00287	CcSEcCtD
Epoprostenol—Cough—Pravastatin—atherosclerosis	0.000735	0.00287	CcSEcCtD
Epoprostenol—Paraesthesia—Lovastatin—atherosclerosis	0.00073	0.00285	CcSEcCtD
Epoprostenol—Arthralgia—Niacin—atherosclerosis	0.000728	0.00284	CcSEcCtD
Epoprostenol—Myalgia—Niacin—atherosclerosis	0.000728	0.00284	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000726	0.00284	CcSEcCtD
Epoprostenol—Anorexia—Simvastatin—atherosclerosis	0.000724	0.00283	CcSEcCtD
Epoprostenol—Dyspnoea—Lovastatin—atherosclerosis	0.000724	0.00283	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000723	0.00282	CcSEcCtD
Epoprostenol—Insomnia—Ezetimibe—atherosclerosis	0.000721	0.00282	CcSEcCtD
Epoprostenol—Arthralgia—Pravastatin—atherosclerosis	0.000717	0.0028	CcSEcCtD
Epoprostenol—Chest pain—Pravastatin—atherosclerosis	0.000717	0.0028	CcSEcCtD
Epoprostenol—Myalgia—Pravastatin—atherosclerosis	0.000717	0.0028	CcSEcCtD
Epoprostenol—Paraesthesia—Ezetimibe—atherosclerosis	0.000716	0.0028	CcSEcCtD
Epoprostenol—Dyspepsia—Lovastatin—atherosclerosis	0.000715	0.00279	CcSEcCtD
Epoprostenol—Anxiety—Pravastatin—atherosclerosis	0.000714	0.00279	CcSEcCtD
Epoprostenol—Dry mouth—Niacin—atherosclerosis	0.000712	0.00278	CcSEcCtD
Epoprostenol—Dyspnoea—Ezetimibe—atherosclerosis	0.00071	0.00278	CcSEcCtD
Epoprostenol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000706	0.00276	CcSEcCtD
Epoprostenol—Decreased appetite—Lovastatin—atherosclerosis	0.000706	0.00276	CcSEcCtD
Epoprostenol—Dyspepsia—Ezetimibe—atherosclerosis	0.000701	0.00274	CcSEcCtD
Epoprostenol—Fatigue—Lovastatin—atherosclerosis	0.0007	0.00274	CcSEcCtD
Epoprostenol—Anaphylactic shock—Niacin—atherosclerosis	0.000698	0.00273	CcSEcCtD
Epoprostenol—Oedema—Niacin—atherosclerosis	0.000698	0.00273	CcSEcCtD
Epoprostenol—Pain—Lovastatin—atherosclerosis	0.000695	0.00271	CcSEcCtD
Epoprostenol—Constipation—Lovastatin—atherosclerosis	0.000695	0.00271	CcSEcCtD
Epoprostenol—Confusional state—Pravastatin—atherosclerosis	0.000693	0.00271	CcSEcCtD
Epoprostenol—Decreased appetite—Ezetimibe—atherosclerosis	0.000693	0.00271	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000692	0.00271	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000688	0.00269	CcSEcCtD
Epoprostenol—Asthenia—Rosuvastatin—atherosclerosis	0.000688	0.00269	CcSEcCtD
Epoprostenol—Insomnia—Simvastatin—atherosclerosis	0.000687	0.00269	CcSEcCtD
Epoprostenol—Anaphylactic shock—Pravastatin—atherosclerosis	0.000687	0.00268	CcSEcCtD
Epoprostenol—Oedema—Pravastatin—atherosclerosis	0.000687	0.00268	CcSEcCtD
Epoprostenol—Fatigue—Ezetimibe—atherosclerosis	0.000687	0.00268	CcSEcCtD
Epoprostenol—Shock—Niacin—atherosclerosis	0.000687	0.00268	CcSEcCtD
Epoprostenol—Infection—Pravastatin—atherosclerosis	0.000683	0.00267	CcSEcCtD
Epoprostenol—Paraesthesia—Simvastatin—atherosclerosis	0.000682	0.00267	CcSEcCtD
Epoprostenol—Pain—Ezetimibe—atherosclerosis	0.000681	0.00266	CcSEcCtD
Epoprostenol—Constipation—Ezetimibe—atherosclerosis	0.000681	0.00266	CcSEcCtD
Epoprostenol—Tachycardia—Niacin—atherosclerosis	0.000681	0.00266	CcSEcCtD
Epoprostenol—Pruritus—Rosuvastatin—atherosclerosis	0.000678	0.00265	CcSEcCtD
Epoprostenol—Skin disorder—Niacin—atherosclerosis	0.000678	0.00265	CcSEcCtD
Epoprostenol—Dyspnoea—Simvastatin—atherosclerosis	0.000678	0.00265	CcSEcCtD
Epoprostenol—Hyperhidrosis—Niacin—atherosclerosis	0.000675	0.00264	CcSEcCtD
Epoprostenol—Thrombocytopenia—Pravastatin—atherosclerosis	0.000673	0.00263	CcSEcCtD
Epoprostenol—Dyspepsia—Simvastatin—atherosclerosis	0.000669	0.00261	CcSEcCtD
Epoprostenol—Anorexia—Niacin—atherosclerosis	0.000665	0.0026	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000664	0.0026	CcSEcCtD
Epoprostenol—Hyperhidrosis—Pravastatin—atherosclerosis	0.000664	0.0026	CcSEcCtD
Epoprostenol—Decreased appetite—Simvastatin—atherosclerosis	0.000661	0.00258	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000656	0.00256	CcSEcCtD
Epoprostenol—Diarrhoea—Rosuvastatin—atherosclerosis	0.000656	0.00256	CcSEcCtD
Epoprostenol—Fatigue—Simvastatin—atherosclerosis	0.000655	0.00256	CcSEcCtD
Epoprostenol—Anorexia—Pravastatin—atherosclerosis	0.000655	0.00256	CcSEcCtD
Epoprostenol—Hypotension—Niacin—atherosclerosis	0.000652	0.00255	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000652	0.00255	CcSEcCtD
Epoprostenol—Constipation—Simvastatin—atherosclerosis	0.00065	0.00254	CcSEcCtD
Epoprostenol—Pain—Simvastatin—atherosclerosis	0.00065	0.00254	CcSEcCtD
Epoprostenol—Urticaria—Lovastatin—atherosclerosis	0.000645	0.00252	CcSEcCtD
Epoprostenol—Body temperature increased—Lovastatin—atherosclerosis	0.000642	0.00251	CcSEcCtD
Epoprostenol—Abdominal pain—Lovastatin—atherosclerosis	0.000642	0.00251	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000636	0.00248	CcSEcCtD
Epoprostenol—Dizziness—Rosuvastatin—atherosclerosis	0.000634	0.00248	CcSEcCtD
Epoprostenol—Urticaria—Ezetimibe—atherosclerosis	0.000633	0.00247	CcSEcCtD
Epoprostenol—Insomnia—Niacin—atherosclerosis	0.000631	0.00247	CcSEcCtD
Epoprostenol—Abdominal pain—Ezetimibe—atherosclerosis	0.00063	0.00246	CcSEcCtD
Epoprostenol—Body temperature increased—Ezetimibe—atherosclerosis	0.00063	0.00246	CcSEcCtD
Epoprostenol—Paraesthesia—Niacin—atherosclerosis	0.000627	0.00245	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000626	0.00245	CcSEcCtD
Epoprostenol—Dyspnoea—Niacin—atherosclerosis	0.000622	0.00243	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000621	0.00243	CcSEcCtD
Epoprostenol—Insomnia—Pravastatin—atherosclerosis	0.000621	0.00243	CcSEcCtD
Epoprostenol—Somnolence—Niacin—atherosclerosis	0.00062	0.00242	CcSEcCtD
Epoprostenol—Paraesthesia—Pravastatin—atherosclerosis	0.000617	0.00241	CcSEcCtD
Epoprostenol—Dyspepsia—Niacin—atherosclerosis	0.000614	0.0024	CcSEcCtD
Epoprostenol—Dyspnoea—Pravastatin—atherosclerosis	0.000613	0.00239	CcSEcCtD
Epoprostenol—Decreased appetite—Niacin—atherosclerosis	0.000607	0.00237	CcSEcCtD
Epoprostenol—Dyspepsia—Pravastatin—atherosclerosis	0.000605	0.00236	CcSEcCtD
Epoprostenol—Rash—Rosuvastatin—atherosclerosis	0.000605	0.00236	CcSEcCtD
Epoprostenol—Dermatitis—Rosuvastatin—atherosclerosis	0.000604	0.00236	CcSEcCtD
Epoprostenol—Urticaria—Simvastatin—atherosclerosis	0.000604	0.00236	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Niacin—atherosclerosis	0.000602	0.00235	CcSEcCtD
Epoprostenol—Body temperature increased—Simvastatin—atherosclerosis	0.000601	0.00235	CcSEcCtD
Epoprostenol—Abdominal pain—Simvastatin—atherosclerosis	0.000601	0.00235	CcSEcCtD
Epoprostenol—Headache—Rosuvastatin—atherosclerosis	0.000601	0.00235	CcSEcCtD
Epoprostenol—Hypersensitivity—Lovastatin—atherosclerosis	0.000599	0.00234	CcSEcCtD
Epoprostenol—Decreased appetite—Pravastatin—atherosclerosis	0.000597	0.00233	CcSEcCtD
Epoprostenol—Pain—Niacin—atherosclerosis	0.000597	0.00233	CcSEcCtD
Epoprostenol—Fatigue—Pravastatin—atherosclerosis	0.000592	0.00231	CcSEcCtD
Epoprostenol—Constipation—Pravastatin—atherosclerosis	0.000588	0.0023	CcSEcCtD
Epoprostenol—Pain—Pravastatin—atherosclerosis	0.000588	0.0023	CcSEcCtD
Epoprostenol—Hypersensitivity—Ezetimibe—atherosclerosis	0.000587	0.00229	CcSEcCtD
Epoprostenol—Asthenia—Lovastatin—atherosclerosis	0.000583	0.00228	CcSEcCtD
Epoprostenol—Pruritus—Lovastatin—atherosclerosis	0.000575	0.00225	CcSEcCtD
Epoprostenol—Asthenia—Ezetimibe—atherosclerosis	0.000572	0.00223	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Niacin—atherosclerosis	0.000571	0.00223	CcSEcCtD
Epoprostenol—Nausea—Rosuvastatin—atherosclerosis	0.000569	0.00223	CcSEcCtD
Epoprostenol—Pruritus—Ezetimibe—atherosclerosis	0.000564	0.0022	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000562	0.0022	CcSEcCtD
Epoprostenol—Hypersensitivity—Simvastatin—atherosclerosis	0.00056	0.00219	CcSEcCtD
Epoprostenol—Diarrhoea—Lovastatin—atherosclerosis	0.000556	0.00217	CcSEcCtD
Epoprostenol—Urticaria—Niacin—atherosclerosis	0.000554	0.00217	CcSEcCtD
Epoprostenol—Abdominal pain—Niacin—atherosclerosis	0.000552	0.00216	CcSEcCtD
Epoprostenol—Body temperature increased—Niacin—atherosclerosis	0.000552	0.00216	CcSEcCtD
Epoprostenol—Urticaria—Pravastatin—atherosclerosis	0.000546	0.00213	CcSEcCtD
Epoprostenol—Asthenia—Simvastatin—atherosclerosis	0.000545	0.00213	CcSEcCtD
Epoprostenol—Diarrhoea—Ezetimibe—atherosclerosis	0.000545	0.00213	CcSEcCtD
Epoprostenol—Body temperature increased—Pravastatin—atherosclerosis	0.000543	0.00212	CcSEcCtD
Epoprostenol—Abdominal pain—Pravastatin—atherosclerosis	0.000543	0.00212	CcSEcCtD
Epoprostenol—Pruritus—Simvastatin—atherosclerosis	0.000538	0.0021	CcSEcCtD
Epoprostenol—Dizziness—Lovastatin—atherosclerosis	0.000537	0.0021	CcSEcCtD
Epoprostenol—Dizziness—Ezetimibe—atherosclerosis	0.000527	0.00206	CcSEcCtD
Epoprostenol—Diarrhoea—Simvastatin—atherosclerosis	0.00052	0.00203	CcSEcCtD
Epoprostenol—Vomiting—Lovastatin—atherosclerosis	0.000517	0.00202	CcSEcCtD
Epoprostenol—Hypersensitivity—Niacin—atherosclerosis	0.000514	0.00201	CcSEcCtD
Epoprostenol—Rash—Lovastatin—atherosclerosis	0.000512	0.002	CcSEcCtD
Epoprostenol—Dermatitis—Lovastatin—atherosclerosis	0.000512	0.002	CcSEcCtD
Epoprostenol—Headache—Lovastatin—atherosclerosis	0.000509	0.00199	CcSEcCtD
Epoprostenol—Vomiting—Ezetimibe—atherosclerosis	0.000507	0.00198	CcSEcCtD
Epoprostenol—Hypersensitivity—Pravastatin—atherosclerosis	0.000506	0.00198	CcSEcCtD
Epoprostenol—Dizziness—Simvastatin—atherosclerosis	0.000503	0.00196	CcSEcCtD
Epoprostenol—Rash—Ezetimibe—atherosclerosis	0.000502	0.00196	CcSEcCtD
Epoprostenol—Dermatitis—Ezetimibe—atherosclerosis	0.000502	0.00196	CcSEcCtD
Epoprostenol—Asthenia—Niacin—atherosclerosis	0.000501	0.00196	CcSEcCtD
Epoprostenol—Headache—Ezetimibe—atherosclerosis	0.000499	0.00195	CcSEcCtD
Epoprostenol—Pruritus—Niacin—atherosclerosis	0.000494	0.00193	CcSEcCtD
Epoprostenol—Asthenia—Pravastatin—atherosclerosis	0.000493	0.00193	CcSEcCtD
Epoprostenol—Pruritus—Pravastatin—atherosclerosis	0.000486	0.0019	CcSEcCtD
Epoprostenol—Vomiting—Simvastatin—atherosclerosis	0.000483	0.00189	CcSEcCtD
Epoprostenol—Nausea—Lovastatin—atherosclerosis	0.000483	0.00189	CcSEcCtD
Epoprostenol—Rash—Simvastatin—atherosclerosis	0.000479	0.00187	CcSEcCtD
Epoprostenol—Dermatitis—Simvastatin—atherosclerosis	0.000479	0.00187	CcSEcCtD
Epoprostenol—Diarrhoea—Niacin—atherosclerosis	0.000477	0.00187	CcSEcCtD
Epoprostenol—Headache—Simvastatin—atherosclerosis	0.000476	0.00186	CcSEcCtD
Epoprostenol—Nausea—Ezetimibe—atherosclerosis	0.000473	0.00185	CcSEcCtD
Epoprostenol—Diarrhoea—Pravastatin—atherosclerosis	0.00047	0.00184	CcSEcCtD
Epoprostenol—Dizziness—Niacin—atherosclerosis	0.000461	0.0018	CcSEcCtD
Epoprostenol—Dizziness—Pravastatin—atherosclerosis	0.000454	0.00178	CcSEcCtD
Epoprostenol—Nausea—Simvastatin—atherosclerosis	0.000451	0.00176	CcSEcCtD
Epoprostenol—Vomiting—Niacin—atherosclerosis	0.000444	0.00173	CcSEcCtD
Epoprostenol—Rash—Niacin—atherosclerosis	0.00044	0.00172	CcSEcCtD
Epoprostenol—Dermatitis—Niacin—atherosclerosis	0.00044	0.00172	CcSEcCtD
Epoprostenol—Headache—Niacin—atherosclerosis	0.000437	0.00171	CcSEcCtD
Epoprostenol—Vomiting—Pravastatin—atherosclerosis	0.000437	0.00171	CcSEcCtD
Epoprostenol—Rash—Pravastatin—atherosclerosis	0.000433	0.00169	CcSEcCtD
Epoprostenol—Dermatitis—Pravastatin—atherosclerosis	0.000433	0.00169	CcSEcCtD
Epoprostenol—Headache—Pravastatin—atherosclerosis	0.00043	0.00168	CcSEcCtD
Epoprostenol—Nausea—Niacin—atherosclerosis	0.000414	0.00162	CcSEcCtD
Epoprostenol—Nausea—Pravastatin—atherosclerosis	0.000408	0.00159	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—CCR2—atherosclerosis	6.51e-05	0.000217	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCR2—atherosclerosis	6.51e-05	0.000217	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CYBA—atherosclerosis	6.48e-05	0.000216	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CYBA—atherosclerosis	6.48e-05	0.000216	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CG—atherosclerosis	6.42e-05	0.000214	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CG—atherosclerosis	6.42e-05	0.000214	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AGT—atherosclerosis	6.36e-05	0.000212	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—INS—atherosclerosis	6.36e-05	0.000212	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GHRL—atherosclerosis	6.34e-05	0.000211	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PLAT—atherosclerosis	6.34e-05	0.000211	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PLAT—atherosclerosis	6.34e-05	0.000211	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PARP1—atherosclerosis	6.34e-05	0.000211	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PARP1—atherosclerosis	6.34e-05	0.000211	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GHRL—atherosclerosis	6.34e-05	0.000211	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CG—atherosclerosis	6.33e-05	0.000211	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—MAPK3—atherosclerosis	6.24e-05	0.000208	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—APOE—atherosclerosis	6.23e-05	0.000207	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CAV1—atherosclerosis	6.17e-05	0.000206	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—APOA1—atherosclerosis	6.16e-05	0.000205	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—atherosclerosis	6.15e-05	0.000205	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—F2—atherosclerosis	6.09e-05	0.000203	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—F2—atherosclerosis	6.09e-05	0.000203	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—atherosclerosis	6.07e-05	0.000202	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TGFB1—atherosclerosis	6.06e-05	0.000202	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KNG1—atherosclerosis	6.05e-05	0.000201	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AGTR1—atherosclerosis	6.01e-05	0.0002	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CCL2—atherosclerosis	5.9e-05	0.000196	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PLG—atherosclerosis	5.86e-05	0.000195	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SERPINE1—atherosclerosis	5.84e-05	0.000194	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—atherosclerosis	5.83e-05	0.000194	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5AP—atherosclerosis	5.83e-05	0.000194	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G2A—atherosclerosis	5.83e-05	0.000194	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOA2—atherosclerosis	5.83e-05	0.000194	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CG—atherosclerosis	5.83e-05	0.000194	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CG—atherosclerosis	5.83e-05	0.000194	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ABCG5—atherosclerosis	5.76e-05	0.000192	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—MAPK3—atherosclerosis	5.74e-05	0.000191	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CG—atherosclerosis	5.62e-05	0.000187	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOS3—atherosclerosis	5.57e-05	0.000186	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TGFB1—atherosclerosis	5.57e-05	0.000186	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KNG1—atherosclerosis	5.56e-05	0.000185	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KNG1—atherosclerosis	5.56e-05	0.000185	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—LPA—atherosclerosis	5.56e-05	0.000185	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SOCS3—atherosclerosis	5.55e-05	0.000185	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AGTR1—atherosclerosis	5.53e-05	0.000184	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AGTR1—atherosclerosis	5.53e-05	0.000184	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PPARG—atherosclerosis	5.43e-05	0.000181	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCL2—atherosclerosis	5.43e-05	0.000181	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCL2—atherosclerosis	5.43e-05	0.000181	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PLG—atherosclerosis	5.39e-05	0.000179	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PLG—atherosclerosis	5.39e-05	0.000179	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP3—atherosclerosis	5.36e-05	0.000178	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOA5—atherosclerosis	5.33e-05	0.000178	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF2—atherosclerosis	5.33e-05	0.000178	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—INS—atherosclerosis	5.32e-05	0.000177	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOB—atherosclerosis	5.18e-05	0.000172	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G1B—atherosclerosis	5.14e-05	0.000171	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCL8—atherosclerosis	5.13e-05	0.000171	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SOCS3—atherosclerosis	5.11e-05	0.00017	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SOCS3—atherosclerosis	5.11e-05	0.00017	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—atherosclerosis	5.1e-05	0.00017	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EDN1—atherosclerosis	5.1e-05	0.00017	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LDLRAP1—atherosclerosis	5.07e-05	0.000169	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCL5—atherosclerosis	5.06e-05	0.000168	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	4.96e-05	0.000165	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—LPL—atherosclerosis	4.94e-05	0.000165	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP3—atherosclerosis	4.93e-05	0.000164	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP3—atherosclerosis	4.93e-05	0.000164	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF2—atherosclerosis	4.91e-05	0.000163	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF2—atherosclerosis	4.91e-05	0.000163	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ALB—atherosclerosis	4.88e-05	0.000163	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PRKCG—atherosclerosis	4.81e-05	0.00016	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLTP—atherosclerosis	4.77e-05	0.000159	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOB—atherosclerosis	4.77e-05	0.000159	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOB—atherosclerosis	4.77e-05	0.000159	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL8—atherosclerosis	4.72e-05	0.000157	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL8—atherosclerosis	4.72e-05	0.000157	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EDN1—atherosclerosis	4.69e-05	0.000156	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EDN1—atherosclerosis	4.69e-05	0.000156	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SPP1—atherosclerosis	4.68e-05	0.000156	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—NOS3—atherosclerosis	4.67e-05	0.000155	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL8—atherosclerosis	4.66e-05	0.000155	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL5—atherosclerosis	4.65e-05	0.000155	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL5—atherosclerosis	4.65e-05	0.000155	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LPL—atherosclerosis	4.55e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LPL—atherosclerosis	4.55e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PRKCG—atherosclerosis	4.42e-05	0.000147	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PRKCG—atherosclerosis	4.42e-05	0.000147	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	4.42e-05	0.000147	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	4.39e-05	0.000146	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	4.37e-05	0.000145	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PDGFB—atherosclerosis	4.33e-05	0.000144	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SPP1—atherosclerosis	4.31e-05	0.000143	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SPP1—atherosclerosis	4.31e-05	0.000143	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—atherosclerosis	4.29e-05	0.000143	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—atherosclerosis	4.29e-05	0.000143	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—atherosclerosis	4.27e-05	0.000142	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	4.26e-05	0.000142	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AGT—atherosclerosis	4.23e-05	0.000141	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—atherosclerosis	4.21e-05	0.00014	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—LEP—atherosclerosis	4.14e-05	0.000138	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOE—atherosclerosis	4.14e-05	0.000138	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LTA4H—atherosclerosis	4.14e-05	0.000138	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCG8—atherosclerosis	4.14e-05	0.000138	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CAV1—atherosclerosis	4.11e-05	0.000137	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOA1—atherosclerosis	4.1e-05	0.000136	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	4.08e-05	0.000136	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PDGFB—atherosclerosis	3.99e-05	0.000133	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PDGFB—atherosclerosis	3.99e-05	0.000133	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—atherosclerosis	3.98e-05	0.000132	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ESR1—atherosclerosis	3.96e-05	0.000132	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—F2—atherosclerosis	3.91e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AGT—atherosclerosis	3.89e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AGT—atherosclerosis	3.89e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—atherosclerosis	3.87e-05	0.000129	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	3.86e-05	0.000128	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LEP—atherosclerosis	3.81e-05	0.000127	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOE—atherosclerosis	3.81e-05	0.000127	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LEP—atherosclerosis	3.81e-05	0.000127	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOE—atherosclerosis	3.81e-05	0.000127	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK3—atherosclerosis	3.8e-05	0.000127	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CAV1—atherosclerosis	3.78e-05	0.000126	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CAV1—atherosclerosis	3.78e-05	0.000126	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOA1—atherosclerosis	3.77e-05	0.000126	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOA1—atherosclerosis	3.77e-05	0.000126	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CG—atherosclerosis	3.74e-05	0.000125	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFB1—atherosclerosis	3.69e-05	0.000123	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ESR1—atherosclerosis	3.64e-05	0.000121	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ESR1—atherosclerosis	3.64e-05	0.000121	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—F2—atherosclerosis	3.6e-05	0.00012	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—F2—atherosclerosis	3.6e-05	0.00012	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK3—atherosclerosis	3.58e-05	0.000119	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—INS—atherosclerosis	3.54e-05	0.000118	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCL2—atherosclerosis	3.48e-05	0.000116	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CG—atherosclerosis	3.44e-05	0.000115	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CG—atherosclerosis	3.44e-05	0.000115	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	3.44e-05	0.000114	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1—atherosclerosis	3.42e-05	0.000114	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK3—atherosclerosis	3.3e-05	0.00011	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK3—atherosclerosis	3.3e-05	0.00011	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCG1—atherosclerosis	3.27e-05	0.000109	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—INS—atherosclerosis	3.26e-05	0.000108	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—INS—atherosclerosis	3.26e-05	0.000108	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SERPINE1—atherosclerosis	3.25e-05	0.000108	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL2—atherosclerosis	3.21e-05	0.000107	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL2—atherosclerosis	3.21e-05	0.000107	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1—atherosclerosis	3.15e-05	0.000105	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1—atherosclerosis	3.15e-05	0.000105	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOS3—atherosclerosis	3.1e-05	0.000103	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—FABP4—atherosclerosis	3.07e-05	0.000102	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LCAT—atherosclerosis	3.07e-05	0.000102	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOA4—atherosclerosis	3.02e-05	0.0001	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SERPINE1—atherosclerosis	2.99e-05	9.96e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SERPINE1—atherosclerosis	2.99e-05	9.96e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP7A1—atherosclerosis	2.96e-05	9.87e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOS3—atherosclerosis	2.86e-05	9.51e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOS3—atherosclerosis	2.86e-05	9.51e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	2.83e-05	9.41e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—atherosclerosis	2.78e-05	9.25e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—atherosclerosis	2.75e-05	9.17e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP27A1—atherosclerosis	2.74e-05	9.12e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	2.7e-05	8.98e-05	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—atherosclerosis	2.66e-05	8.86e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	2.63e-05	8.76e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—atherosclerosis	2.62e-05	8.72e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALOX5AP—atherosclerosis	2.6e-05	8.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLA2G2A—atherosclerosis	2.6e-05	8.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOA2—atherosclerosis	2.6e-05	8.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALOX15—atherosclerosis	2.6e-05	8.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCG5—atherosclerosis	2.57e-05	8.54e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	2.56e-05	8.53e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—atherosclerosis	2.56e-05	8.53e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—atherosclerosis	2.53e-05	8.44e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—atherosclerosis	2.53e-05	8.44e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—atherosclerosis	2.49e-05	8.29e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LPA—atherosclerosis	2.48e-05	8.25e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NFKB1—atherosclerosis	2.46e-05	8.21e-05	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—atherosclerosis	2.45e-05	8.15e-05	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—atherosclerosis	2.45e-05	8.15e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK8—atherosclerosis	2.42e-05	8.07e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—atherosclerosis	2.42e-05	8.04e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—atherosclerosis	2.41e-05	8.02e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—atherosclerosis	2.41e-05	8.02e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—BGN—atherosclerosis	2.4e-05	7.99e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	2.38e-05	7.93e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOA5—atherosclerosis	2.38e-05	7.91e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	2.31e-05	7.68e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—atherosclerosis	2.29e-05	7.63e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—atherosclerosis	2.29e-05	7.63e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	2.29e-05	7.61e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NFKB1—atherosclerosis	2.27e-05	7.55e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NFKB1—atherosclerosis	2.27e-05	7.55e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	2.26e-05	7.53e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	2.24e-05	7.46e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—atherosclerosis	2.24e-05	7.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	2.24e-05	7.44e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK8—atherosclerosis	2.23e-05	7.42e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK8—atherosclerosis	2.23e-05	7.42e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—atherosclerosis	2.22e-05	7.4e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—atherosclerosis	2.22e-05	7.4e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—atherosclerosis	2.21e-05	7.37e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALOX5—atherosclerosis	2.21e-05	7.35e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—atherosclerosis	2.15e-05	7.15e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK3—atherosclerosis	2.12e-05	7.05e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—atherosclerosis	2.06e-05	6.85e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—atherosclerosis	2.06e-05	6.85e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—atherosclerosis	2.05e-05	6.84e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	2.04e-05	6.79e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—atherosclerosis	2.04e-05	6.79e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—atherosclerosis	2.04e-05	6.79e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NAMPT—atherosclerosis	1.98e-05	6.6e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.97e-05	6.56e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LIPC—atherosclerosis	1.97e-05	6.55e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOC3—atherosclerosis	1.96e-05	6.51e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK3—atherosclerosis	1.95e-05	6.48e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK3—atherosclerosis	1.95e-05	6.48e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LDLR—atherosclerosis	1.94e-05	6.47e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CETP—atherosclerosis	1.9e-05	6.32e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—atherosclerosis	1.89e-05	6.29e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—atherosclerosis	1.89e-05	6.29e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SCARB1—atherosclerosis	1.82e-05	6.06e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.77e-05	5.9e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMGCR—atherosclerosis	1.72e-05	5.72e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.55e-05	5.16e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—atherosclerosis	1.55e-05	5.15e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCA1—atherosclerosis	1.53e-05	5.1e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—atherosclerosis	1.43e-05	4.75e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—atherosclerosis	1.42e-05	4.74e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—atherosclerosis	1.42e-05	4.74e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMOX1—atherosclerosis	1.31e-05	4.37e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—atherosclerosis	1.31e-05	4.37e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—atherosclerosis	1.31e-05	4.37e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOB—atherosclerosis	1.26e-05	4.19e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—atherosclerosis	1.22e-05	4.08e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LPL—atherosclerosis	1.2e-05	4e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX1—atherosclerosis	1.17e-05	3.9e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CD36—atherosclerosis	1.14e-05	3.8e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—atherosclerosis	1.08e-05	3.6e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARA—atherosclerosis	1.06e-05	3.53e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AGT—atherosclerosis	1.03e-05	3.42e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOE—atherosclerosis	1.01e-05	3.35e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CAV1—atherosclerosis	9.98e-06	3.32e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOA1—atherosclerosis	9.95e-06	3.31e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CG—atherosclerosis	9.09e-06	3.03e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARG—atherosclerosis	8.77e-06	2.92e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—INS—atherosclerosis	8.6e-06	2.86e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—atherosclerosis	7.89e-06	2.63e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NOS3—atherosclerosis	7.54e-06	2.51e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—atherosclerosis	6.9e-06	2.3e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—atherosclerosis	3.47e-06	1.15e-05	CbGpPWpGaD
